Cancer Family
Invasive Malignant Neoplasm
CI-CAN-00000213Explore in graph →
604 active trials9 approved drugs37 evidence items
- NCIt
- C8505
Loading cancer entity…
Cancer Family
CI-CAN-00000213Explore in graph →
Clinical trials
1,820 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06067269 | Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial(HEATWAVE) | recruiting | Phase 2 | 95 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03113487 | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 |
| Jul 16, 2026 |
| clinicaltrials |
| NCT03579316 | Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03744793 | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05092373 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | recruiting | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05465941 | PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | active not recruiting | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02276443 | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | active not recruiting | N/A | 798 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02411656 | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | active not recruiting | Phase 2 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02912312 | Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer | active not recruiting | Phase 2 | 805 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05691465 | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05057715 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | active not recruiting | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07137416 | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer | recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03180294 | Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer | completed | Phase 2 | 230 | NRG OncologyOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04037254 | Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring | completed | Phase 1 / Phase 2 | 22 | NRG OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT03274687 | Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer | completed | Phase 3 | 296 | NRG OncologyOTHER | 3 | Jul 9, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03587311 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05607004 | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer(EVANGELINE) | active not recruiting | Phase 2 | 87 | Atossa Therapeutics, Inc.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT01883297 | "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 3 | University Health Network, TorontoOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04175431 | Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study | recruiting | Phase 2 | 100 | University of WashingtonOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04624256 | Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial(GARUDA) | active not recruiting | N/A | 208 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05521698 | A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer | recruiting | Phase 1 | 80 | University of Wisconsin, MadisonOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06994195 | A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) | recruiting | Phase 3 | 450 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT02623972 | A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | active not recruiting | Phase 2 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07042256 | Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer(HIP-PRO) | recruiting | N/A | 13 | University of ZurichOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07226427 | A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer | recruiting | Phase 1 | 100 | Stemline Therapeutics, Inc.INDUSTRY | 3 | Jul 6, 2026 | clinicaltrials |
| NCT07302230 | Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial(EMPOWER) | recruiting | N/A | 100 | University of WashingtonOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07552168 | INSPIRE: INnovative SABR for Prostate Cancer All IREland | recruiting | Phase 2 | 136 | Cancer Trials IrelandNETWORK | 2 | Jul 6, 2026 | clinicaltrials |
| NCT02346253 | High-Dose Brachytherapy in Treating Patients With Prostate Cancer | completed | N/A | 146 | Stanford UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05852041 | rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance | recruiting | Early Phase 1 | 40 | Northwestern UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06813898 | An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial | recruiting | Early Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02957968 | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | active not recruiting | Phase 2 | 46 | Virginia Commonwealth UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05429970 | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | recruiting | N/A | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03012100 | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | active not recruiting | Phase 2 | 280 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07674615 | IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer | not yet recruiting | Phase 1 | 19 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04387227 | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07545460 | A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07574489 | Whole Versus Partial Gland Boost During Prostate SBRT | not yet recruiting | Phase 2 / Phase 3 | 186 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT01750073 | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer | completed | Phase 2 | 92 | University of NebraskaOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT02217709 | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | completed | Phase 2 | 26 | University of Southern CaliforniaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04530552 | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07664735 | A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | not yet recruiting | Phase 1 | 30 | Outpace Bio, Inc.INDUSTRY | 0 | Jun 24, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT04414202 | Observational Study of Intra-operative Partial Irradiation of Invasive Ductal Breast Carcinomas With a Good Prognosis(INTRA-OBS) | active not recruiting | — | 519 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 17, 2026source: clinicaltrials